SIR, While rituximab is effective to treat RA, there is no evidence that it might be useful in treating AS [1] . Here, we report the successful treatment of a patient with AS and hepatitis B infection with rituximab.
A woman was diagnosed with AS (HLA-B27 positive) in 1993, when she was 28 yrs old. She first visited our consultancy due to inflammatory lower back pain that had evolved over 6 months. She suffered for years a chronic state of AS characterized by inflammatory lower back pain, bilateral sacroiliitis (symmetrical, radiological stage 3; Fig. 1 ), symmetrical arthritis in the hands, shoulders and knees, morning stiffness lasting longer than 30 min and global pain measured as about 70 in the visual analogue scale (VAS 0-100). Analyses to detect RF and anti-cyclic citrullinated peptide (anti-CCP) antibodies were both negative. She had suffered four episodes of episcleritis and uveitis that were treated with cycloplegics and topical steroids. She had also been treated with NSAIDs and with SSZ, MTX and LEF in monotherapy, treatments that were suspended due to digestive intolerance or elevated transaminases. In April 2006, a hepatitis B virus (HBV) infection was detected: HBsAg positive, anti-HBs Ac negative, anti-HBc IgG positive, anti-HBc IgM negative, HBeAg negative, anti-HBe positive with undetectable viral load (<12 UI/ml), and there was an increase in liver enzymes: aspartate aminotransferase 348 U/l (normal 15-51), alanine aminotransferase 96 U/l (normal 14-57), -glutamyl transpeptidase 1738 U/l (normal 7-50), alkaline phosphatase 198 U/l (normal 38-174). However, no hepatitis C or human immunodeficiency virus was detected serologically. She received treatment with lamivudine 100 mg/day and pegylated IFN--2a 180 g/week from April 2006 until January 2007. In May 2007, a Mantoux test [2 U purified protein derivative (PPD)] produced a papule of 15 mm although thoracic X-rays were normal. She rejected the use of TNFantagonists in order to avoid taking isoniazid for the fear of suffering toxic hepatitis, but she signed an informed consent form in June 2007 for monotherapeutic treatment with rituximab (two infusions of 1 g with 8 mg of dexamethasone separated by 15 days). Prophylactic lamivudine was administered for 3 months before and after the infusion. A few weeks after infusion, a rapid clinical improvement was produced (Table 1) and since then, she has only required treatment with metamizole (1.725 mg/day).
The clinical and analytical improvement in this patient suggests that anti-CD20 therapy could be effective in treating patients with AS that is resistant to conventional therapies. This effect could reflect the reduction in the production of pro-inflammatory cytokines provoked by CD20þ cell depletion, including TNF-, IL-1 and IL-6, as well as by interference with other cell systems [2].
It does not seem likely that this result is related to the two doses of steroids administered during the infusions since their effect would have been transient.
The case of a patient with AS that did not improve when administered rituximab has been published very recently [1] . However, unlike our patient this case represented a particularly resistant condition with purely axial affectation that had not previously improved with any type of treatment, including pamidronate and three changes of anti-TNF. In contrast, our patient had fairly prominent peripheral arthritis as well as inflammatory lower back pain, and she had still not received anti-TNF treatment. Perhaps the peripheral manifestations of AS respond better to rituximab, as has been seen with other treatments [3] . Despite the fact that such prominent symmetric arthritis is atypical at this stage of the disease, our patient complied with the criteria of AS. Indeed, we believe that it is unlikely that this condition coexisted with RA both because such a phenomenon is very rare and because antibodies against CCP and RF could not be detected [4] .
HBV reactivation has been reported in sporadic patients treated with rituximab. Although the viral load in this patient became positive despite the administration of lamivudine, no hepatocyte damage was observed.
As far as we know, this is the first case of AS successfully treated with rituximab, suggesting that the use of rituximab to treat active AS should perhaps be addressed in clinical trials. Ankylosing spondylitis and pulmonary sarcoidosis-a case report and discussion of the literature SIR, Co-occurrence of sacroiliitis and sarcoidosis is rarely reported, but when it occurs it is a cause of diagnostic confusion [1] . The two conditions may co-exist either due to sarcoid deposition within the SI joint or due to the development of two distinct conditions (sarcoid and SpA) within the same patient [1] . Recent reports of the development of pulmonary sarcoidosis in patients with AS treated with anti-TNF-therapy makes correct diagnosis in these cases critical [2, 3] . We present the case of a 31-yr-old man with a 23-yr history of AS, who was found to have radiological and histological evidence of pulmonary sarcoidosis while undergoing preliminary assessment for anti-TNF-therapy.
The patient came under the care of our clinic in 1999. Plain radiographs at that time showed sclerosis and ankylosis of both SI joints (Fig. 1a) , and Schober's test and chest expansion were well maintained at 5 cm. Auscultation of the chest was normal. Initially he was managed with oral naproxen and physiotherapy. Oral SSZ was started when his symptoms worsened.
In 2005, he reported increasing spinal pain and stiffness and examination revealed that his spinal movements had deteriorated, with Schober's test and chest expansion at 2 cm. At this point, the use of TNF-blocking therapy was discussed with the patient. A routine chest radiograph at this time, however, revealed reticularnodular shadowing mainly in the mid-and upper zones (Fig. 1b) . High-resolution CT scanning of the lungs showed enlarged mediastinal and hilar lymph nodes with extensive mid-and upper zone fibrosis consistent with pulmonary sarcoidosis. Transbronchial lung biopsy revealed non-necrotizing granulomata and bronchioalveolar lavage revealed a chronic inflammatory picture. There was no evidence of tuberculosis on prolonged culture. Pulmonary function tests showed an FEV1 of 2.73 l (69% of predicted), an FVC of 3.0 l (62% of predicted) and a transfer factor of 1.68 (107% of predicted). There were no previous chest radiographs within the hospital for comparison. Direct questioning revealed that the patient had had symptoms of breathlessness since adolescence, but had not reported this and had modified his activities to avoid exertion. Later in life he had found that his spinal symptoms were the main limit to his activity.
Tissue typing revealed that along with HLA B27 the patient carried DR4, which has been associated with late onset of sarcoidosis, and DQB1 Ã 06, which has been associated with susceptibility to sarcoid [4] .
There have been only five other reported cases of sarcoidosis developing in a patient with established AS [1, [5] [6] [7] . All of these patients were HLA-B27 positive and presented initially with sacroiliitis but then went on to develop pulmonary sarcoidosis (in one case with skin nodules [1]) with non-necrotizing granulomata on lung biopsy. There have been nine reported cases (six before 1975) in which features of SpA and sarcoidosis have co-existed [1, 5, 6, 8] . In one case, biopsy of the SI joint revealed sarcoid, and in the four cases where HLA typing was available, all were B27 negative but carried HLA types that have been associated with sarcoidosis (B8, B13, B35 and A9), making sarcoid of the SI joint the most likely diagnosis.
A recent cross-sectional study of a UK sarcoid population found that radiological sacroiliitis occurred in 6.6% of the patients compared with 1.9% of the normal population [9] . These data, however, do not support a true association between SpA and sarcoidosis, as only one of the four patients found to 
